Profillin‐1 and Transgelin‐2: Actin Binding Proteins Expression in Early and Advanced Stages of Triple‐Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Documenti analoghi

• Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer Using Pre-Treatment Histopathologic Images
  di: Khan, Hikmat, et al.
  Pubblicazione: (2025)
• Prognostic and Predictive Markers for Early Stage Triple‐Negative Breast Cancer Treated With Platinum‐Based Neoadjuvant Chemotherapy
  di: Zhenhui Zhao, et al.
  Pubblicazione: (2024)
• Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response
  di: Milena Martello Cristófalo, et al.
  Pubblicazione: (2026)
• Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple‐Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden
  di: Atif Ali Hashmi, et al.
  Pubblicazione: (2025)
• Collagen Density Is Associated With Pathological Complete Response to Neoadjuvant Chemotherapy in Triple‐Negative Breast Cancer Patients
  di: Fengling Li, et al.
  Pubblicazione: (2024)